All In Biotech

NDA 213895 · Hikma

Vancomycin

Vancomycin · Intravenous, Oral

Priority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Aug 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 26, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

123 Phase 3, 64 recruiting

FAERS reports

65,564

60,431 serious, 12,910 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 26, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabelReview
1 products under this application
  • VANCOMYCIN · VANCOMYCIN 5GM/100ML (50MG/ML) · SOLUTION, INTRAVENOUS, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,429
  • acute kidney injury4,911
  • off label use4,760
  • pyrexia4,067
  • drug reaction with eosinophilia and systemic symptoms2,707
  • renal failure2,435
  • diarrhoea2,373
  • sepsis2,360
  • condition aggravated2,220
  • pneumonia2,210
  • rash2,186
  • hypotension2,167

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004859
2005914
20061,010
2007870
20081,115
20091,029
20101,332
20111,905
20121,897
20131,859
20141,939
20152,457
20162,759
20173,352
20184,563
20194,401
20205,226
20215,112
20224,843
20234,912
20245,153
20254,995
20263,057

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vancomycin (Vancomycin HCl In 5 % Dextrose)

2024 spending

$25K

Beneficiaries

164

462 claims

Per beneficiary

$150

$0.09 per unit

View as table
YearSpending
2020$91,490
2021$76,407
2022$38,571
2023$30,391
2024$24,582

Part B: Vancomycin* (Vancomycin HCL In 5 % Dextrose*) · HCPCS J3370

2024 spending

$159K

Beneficiaries

5,120

16,321 claims

Per beneficiary

$31

2024 ASP limit $2.26 per unit

View as table
YearSpending
2020$1,208,310
2021$413,086
2022$269,586
2023$189,445
2024$159,482

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,708 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.